IDiyas

For the Inventor, By the Inventor

Frankfurt am Main, Germany

Bruno Baumgartner

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 5.7

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Frankfurth am Main, DE (2014)
  • Frankfurt-am-Main, DE (2013 - 2023)

Company Filing History:

goldMedal8 out of 1,451 
 
Sanofi
 patents

Years Active: 2013-2023

where 'Filed Patents' based on already Granted Patents

8 patents (USPTO):
1. 11590206 - Liquid pharmaceutical composition (2023-02-28),
2. 9145385 - Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid (2015-09-29),
3. 9102657 - Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid (2015-08-11),
4. 9067918 - Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl ]-amide (2015-06-30),
5. 8993602 - Benzoic acid salt of otamixaban (2015-03-31),
6. 8785608 - Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use (2014-07-22),
7. 8710078 - Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride (2014-04-29),
8. 8598201 - Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride (2013-12-03),

Title: The Innovative Contributions of Bruno Baumgartner

Introduction

Bruno Baumgartner, an accomplished inventor located in Frankfurt am Main, Germany, has made significant strides in the pharmaceutical field. With a remarkable portfolio of 8 patents, Baumgartner's work focuses on innovative treatments for various medical conditions.

Latest Patents

Among his latest inventions is a liquid pharmaceutical composition that incorporates a peptide designated as SEQ ID NO.: 2. This composition is tailored for medical applications in humans, particularly in treating disorders related to metabolic syndrome, diabetes, and obesity, as well as aiding in the reduction of excessive food intake. Furthermore, he has developed crystalline salts of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid. This invention relates to a sodium salt of the compound, which is available as a monohydrate or anhydrate in crystalline form and offers innovative methods to treat conditions improved by administering an inhibitor of the enzyme TAFIa.

Career Highlights

Bruno Baumgartner is currently associated with Sanofi, a leading global healthcare company. His dedication to research and development in the pharmaceutical industry has significantly influenced the creation of solutions that address crucial health challenges.

Collaborations

Throughout his career, Baumgartner has collaborated with talented professionals, including Norbert Nagel and Mandy Mohnicke. These partnerships have played a vital role in the success of his inventions and have contributed to advancing medical science.

Conclusion

In summary, Bruno Baumgartner's innovative spirit and commitment to improving healthcare through his inventions have established him as a notable figure in the pharmaceutical industry. With his groundbreaking patents and collaborative efforts, he continues to contribute to the development of effective medical solutions for various conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…